NDUFA6 and acute myeloid leukemia: Accordingly, we inspected whether AML patients with low and high levels of biomarkers as NDUFA6, SDHA, CYB5A, SLC25A12, ETFB and CPT1A have differential leukemic burden in their peripheral blood and bone marrow biospecimens.